Considerations when prescribing trimethoprim-sulfamethoxazole

CMAJ. 2011 Nov 8;183(16):1851-8. doi: 10.1503/cmaj.111152. Epub 2011 Oct 11.

Authors

Joanne M-W Ho¹, David N Juurlink

Affiliation

¹ Division of Clinical Pharmacology, Department of Medicine, University of Toronto, the Institute for Clinical Evaluative Sciences, Toronto, Ont. jmho2001@gmail.com

No abstract available

Publication types

Review

MeSH terms

Abnormalities, Drug-Induced
Anti-Infective Agents / adverse effects*
Anticoagulants / adverse effects
Biomedical Research
Cytochrome P-450 Enzyme System / drug effects
Drug Eruptions
Drug Interactions
Female
Folic Acid Deficiency / chemically induced
Hematologic Diseases / chemically induced
Hemolysis / drug effects
Humans
Hyperkalemia / chemically induced
Hypoglycemia / chemically induced
Hypoglycemic Agents / adverse effects
Immunocompromised Host
Infant, Newborn
Infant, Small for Gestational Age
Kidney / drug effects
Nervous System Diseases / chemically induced
Pregnancy
Trimethoprim, Sulfamethoxazole Drug Combination / adverse effects*
Warfarin / adverse effects

Substances

Anti-Infective Agents
Anticoagulants
Hypoglycemic Agents
Warfarin
Trimethoprim, Sulfamethoxazole Drug Combination
Cytochrome P-450 Enzyme System